Great West Life Assurance Co. Can lifted its position in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 5.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,533 shares of the medical technology company’s stock after purchasing an additional 2,179 shares during the period. Great West Life Assurance Co. Can owned 0.06% of Hill-Rom worth $2,894,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. US Bancorp DE lifted its holdings in Hill-Rom by 4.9% in the second quarter. US Bancorp DE now owns 4,524 shares of the medical technology company’s stock worth $360,000 after buying an additional 212 shares during the period. Russell Investments Group Ltd. lifted its holdings in Hill-Rom by 37.5% in the second quarter. Russell Investments Group Ltd. now owns 86,003 shares of the medical technology company’s stock worth $6,847,000 after buying an additional 23,435 shares during the period. IFP Advisors Inc lifted its holdings in Hill-Rom by 3.0% in the second quarter. IFP Advisors Inc now owns 4,607 shares of the medical technology company’s stock worth $367,000 after buying an additional 135 shares during the period. Canada Pension Plan Investment Board lifted its holdings in Hill-Rom by 42.7% in the second quarter. Canada Pension Plan Investment Board now owns 16,700 shares of the medical technology company’s stock worth $1,329,000 after buying an additional 5,000 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Hill-Rom by 13.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 795,112 shares of the medical technology company’s stock worth $63,299,000 after buying an additional 96,433 shares during the period. Institutional investors own 82.35% of the company’s stock.

Several equities analysts have recently issued reports on HRC shares. Zacks Investment Research upgraded shares of Hill-Rom from a “sell” rating to a “hold” rating in a report on Monday, September 18th. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays lifted their target price on shares of Hill-Rom from $86.00 to $90.00 and gave the company an “overweight” rating in a report on Monday, November 6th. Bank of America reiterated a “hold” rating on shares of Hill-Rom in a report on Wednesday, November 22nd. Finally, Stifel Nicolaus lifted their target price on shares of Hill-Rom from $84.00 to $85.00 and gave the company a “buy” rating in a report on Monday, November 6th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $89.57.

Hill-Rom Holdings, Inc. (NYSE HRC) traded down $0.25 during mid-day trading on Wednesday, hitting $82.59. 411,300 shares of the stock traded hands, compared to its average volume of 501,742. Hill-Rom Holdings, Inc. has a 1 year low of $54.59 and a 1 year high of $85.25. The stock has a market capitalization of $5,452.61, a price-to-earnings ratio of 21.46, a price-to-earnings-growth ratio of 1.76 and a beta of 1.19. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.05. The company had revenue of $738.30 million during the quarter, compared to the consensus estimate of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.18 earnings per share. analysts forecast that Hill-Rom Holdings, Inc. will post 4.26 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be given a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Thursday, December 14th. Hill-Rom’s dividend payout ratio (DPR) is currently 36.18%.

In related news, SVP Andreas G. Frank sold 6,870 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $77.48, for a total transaction of $532,287.60. Following the completion of the sale, the senior vice president now owns 16,701 shares of the company’s stock, valued at $1,293,993.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.20% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/13/great-west-life-assurance-co-can-has-2-89-million-stake-in-hill-rom-holdings-inc-hrc.html.

Hill-Rom Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Stock Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related stocks with our FREE daily email newsletter.